BPG is committed to discovery and dissemination of knowledge
Minireviews Open Access
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Oncol. Nov 24, 2026; 17(11): 125896
Published online Nov 24, 2026. doi: 10.5306/wjco.125896
Autonomic neural reprogramming in pancreatic ductal adenocarcinoma: Putative neurotumoral circuits linking perineural invasion to metastatic progression
Jia-Hui Xie, Jia-Yi Jiang, Jin-Yao Yang, Tong-Tong Zhang, Zi-Mu Li, Yun Liu, Meng-Jiang Lu, Bin Xu, Tian-Cheng Xu, Key Laboratory of Acupuncture and Medicine Research of the Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China
Shuai-Yan Wang, Guan-Hu Yang, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China
ORCID number: Jia-Hui Xie (0009-0000-7968-6575); Shuai-Yan Wang (0009-0008-6041-1334); Jia-Yi Jiang (0009-0008-0662-5681); Jin-Yao Yang (0009-0005-1065-8142); Tong-Tong Zhang (0009-0003-1052-094X); Zi-Mu Li (0009-0009-2033-7544); Yun Liu (0000-0002-0451-184X); Meng-Jiang Lu (0000-0001-8635-4659); Bin Xu (0000-0003-4006-3009); Guan-Hu Yang (0000-0001-7888-5759); Tian-Cheng Xu (0000-0003-0089-0712).
Co-first authors: Jia-Hui Xie and Shuai-Yan Wang.
Co-corresponding authors: Guan-Hu Yang and Tian-Cheng Xu.
Author contributions: Xie JH and Wang SY were responsible for the idea and conceptual framework, they contributed equally to this manuscript and are co-first authors; Xie JH, Wang SY, Jiang JY, Yang JY, Zhang TT and Li ZM wrote the first draft of the manuscript; Wang SY was responsible for drafting the forms and figures; Liu Y, Lu MJ, Yang GH, reviewed the manuscript and critically revised it for important intellectual content; Xu B provided expert guidance on pancreatic neurobiology, while Xu TC provided methodological guidance on literature quality assessment and has expertise in medicine-engineering integration, Yang GH and Xu TC jointly supervised this work and are co-corresponding authors; and all authors have reviewed and approved the final version of the manuscript.
AI contribution statement: We used Doubao and Deepseek to revise individual sentences and conduct native-level linguistic polishing. No AI-generated writing content was used throughout the entire writing and revision process. All AI-modified text has been checked and verified by the authors, who take full responsibility for the accuracy and integrity of this manuscript.
Supported by National Natural Science Foundation of China, No. 82305376; Youth Talent Support Project of the China Acupuncture and Moxibustion Association, No. 2024-2026ZGZJXH-QNRC005; 2024 Jiangsu Province Youth Science and Technology Talent Support Project, No. JSTJ-2024-380; Talent Cultivation Program for Young Researchers, Key Laboratory of the Ministry of Education Project, No. zyqt202501 and No. zyqt202503; Postgraduate Research & Practice Innovation Program of Jiangsu Province, No. KYCX24_2210; and Faculty Research Grant of Macau University of Science and Technology, No. FRG-26-058-FC.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Tian-Cheng Xu, PhD, Academic Fellow, Chairman, Editor, Head, Principal Investigator, Professor, Visiting Professor, Key Laboratory of Acupuncture and Medicine Research of the Ministry of Education, Nanjing University of Chinese Medicine, No. 138 Xianlin Road, Nanjing 210023, Jiangsu Province, China. xtc@njucm.edu.cn
Received: July 22, 2026
Revised: September 3, 2026
Accepted: October 28, 2026
Published online: November 24, 2026
Processing time: 120 Days and 17.8 Hours

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal gastrointestinal malignancy characterized by dense neural innervation and a pronounced tendency for perineural infiltration, pathological features closely associated with poor prognosis and metastatic spread. Recent studies support a model of PDAC as a neurotropic malignant tumor potentially associated with a self-reinforcing autonomic-neural-tumor network-in which sympathetic components, tumor cells, and stromal fibroblasts form an integrated neuro-oncologic network that may contribute to tumor invasiveness, microenvironment adaptation, and metastatic potential. However, evidence for spontaneous distant metastasis and clinically meaningful therapeutic benefit remains limited. This narrative review aims to examine the neuro-oncologic interface in PDAC, focusing on the sympathetic nerve-cancer associated fibroblasts feedback loop model and the PIEZO1-YAP1 mechanotransduction axis, and to discuss how these pathways may contribute to perineural invasion and systemic dissemination, thereby highlighting a potential novel therapeutic strategy.

Key Words: Pancreatic ductal adenocarcinoma; Perineural invasion; Tumor microenvironment; Cancer neuroscience; Mechanotransduction; Metastasis; Sympathetic nerves; Cancer-associated fibroblasts

Core Tip: The pancreatic autonomic nervous system regulates tumor initiation, progression, and metastatic evolution through dynamic bidirectional interactions with cancer cells and the tumor microenvironment. Sympathetic input enhances cancer-associated fibroblast (CAF) activation and extracellular matrix remodeling, whereas activated CAF induce stress and injury-like transcriptional programs in sympathetic neurons, thereby strengthening tumor-supporting neural plasticity. Mechanical signal transduction, such as the activation of the PIEZO1-YAP1 pathway, serves as a key driver of neuroinvasive behavior. Targeting the autonomic-neural-tumor axis represents a promising strategy to suppress perineural invasion and prevent systemic dissemination of pancreatic cancer.



INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal solid tumors. Most patients present with advanced disease, and current systemic therapies provide limited disease control[1]. Perineural invasion (PNI) is frequently detected in resected specimens and is associated with shorter survival and increased recurrence[2].

Recent histological analyses suggest that PNI extent and architecture may provide prognostic information[3]. However, although clinical studies have established this prognostic association, functional studies are needed to determine whether PNI directly affects distant dissemination. Neuron-resolved tracing and transcriptomic studies have described changes in sympathetic and sensory neurons in PDAC, suggesting that sympathetic neurons maintain a “cancer nerve state”[4]. Human spatial profiling has further identified distinct malignant, fibroblast, Schwann cell, myeloid, and lymphoid states surrounding invaded and non-invaded nerves[5]. Together, these observations support the neural microenvironment as a spatially organized component of PDAC progression, although much of this evidence remains descriptive or correlative.

Current evidence links neural remodeling to stromal and mechanical regulation through several experimentally defined pathways. In a mouse PDAC model, catecholamines promoted β2-adrenergic receptor (β2-AR)-dependent PDAC development, nerve growth factor (NGF) secretion, and pancreatic nerve density[6]. Studies in human and mouse pancreatic tumors suggest local bidirectional crosstalk between sympathetic neurons and fibroblasts[7]. Cues associated with myofibroblasts have been implicated in pancreatic inflammation and neoplasia[8-11].

Mechanical signaling forms another layer. In human spatial PDAC series, PIEZO1 was enriched near PNI, and co-culture and nerve-invasion assays using pancreatic cancer cells suggest that PIEZO1 may regulate neurotropic phenotypes[12]. Matrix-stiffness models link PIEZO1 to chemoresistance in PDAC[13]. YAP1 is an established mechanotransducer of cell shape and matrix mechanics[14].

We therefore examine whether current evidence supports the proposed neurotumoral feedback model (Figure 1), which involves sympathetic nerves, CAFs, and PIEZO1-YAP1-mediated mechanotransduction. Three mechanistic questions now define the field: Studies must establish the direction and reproducibility of autonomic regulation of CAFs and extracellular matrix (ECM) programs; test whether these programs drive spontaneous distant metastasis; and determine whether nerve-adjacent PIEZO1-YAP1 activity reflects neural cues, tissue stiffness, spatial confinement, or their combined effects. By integrating these perspectives, we aim to identify therapeutic opportunities and highlight the bottlenecks currently hindering clinical translation.

Figure 1
Figure 1 Proposed neurotumoral feedback loop model involving sympathetic nerves and cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Sympathetic nerves release norepinephrine, which enhances cancer-associated fibroblast (CAF) activation and extracellular matrix (ECM) remodeling. In turn, activated CAFs remodel sympathetic neurons and promote tumor-supporting neural plasticity. ECM reprogramming may alter matrix stiffness. ECM stiffness may be accompanied by PIEZO1 hyperactivation in pancreatic ductal adenocarcinoma tumor cells and downstream YAP1/TEAD signaling. These cellular changes may be associated with enhanced neural invasion and may represent one of the triggers for distant metastasis. PDAC: Pancreatic ductal adenocarcinoma; CAF: Cancer-associated fibroblast; ECM: Extracellular matrix; PNI: Perineural invasion; TEAD: Transcriptional enhanced associate domain. This figure was created by BioRender.com (Supplementary material).
REVIEW METHODS

To supplement this narrative review, we searched PubMed and Google Scholar on 30 June 2026 for publications from 2021 to that date. PubMed searches combined Medical Subject Headings with title and abstract terms. For each query, we used Google Scholar to collect the first 100 results, ranked by relevance. Representative search themes included PDAC, PNI, autonomic neural signaling, Schwann cells, CAFs, ECM remodeling, PIEZO1-YAP mechanotransduction, and related therapeutic interventions.

Following deduplication, records underwent title and abstract screening, followed by full-text assessment where relevant. Selection criteria prioritized peer-reviewed original studies in patients with PDAC or relevant experimental models, including studies reporting negative or conflicting findings. Reviews and foundational studies in other biological settings provide contextual evidence. If the search within the most recent five years does not retrieve sufficient high-quality evidence directly relevant to our question, the search dates and coverage will be judiciously extended to include earlier studies. No language filter was applied; non-English reports requiring translation remained pending until their content could be reliably assessed. Preprints and conference abstracts were used to identify corresponding peer-reviewed full reports and were not treated as core evidence themselves.

CHARACTERISTICS OF THE PDAC MICROENVIRONMENT: AUTONOMIC NERVE–TUMOR FEEDBACK LOOP NETWORK

The PDAC tumor microenvironment comprises tumor cells, autonomic nerves, CAFs, and a continuously remodeling ECM. These elements engage in reciprocal crosstalk: Tumor cells induce structural and functional changes in local autonomic nerves, which subsequently influence stromal compartments. Among the stromal players, CAFs act as a nexus between neural cues and matrix remodeling, whereas ECM dynamics further shape the physical niche and fine-tune tumor-nerve communication. The resultant multidirectional interactions establish a self-sustaining autonomic-nerve-tumor feedback loop. This circuit fuels malignancy, promotes PNI, and increases the likelihood of metastatic spread.

Pancreatic sympathetic nerves: The central neural component of the autonomic nerve-tumor feedback loop model in PDAC PNI

Neural regulation of PNI in PDAC involves distinct nerve types with context-dependent effects. Sympathetic nerves release norepinephrine (NE), which activates adrenergic receptors (AR) on tumor cells, thereby directly promoting tumor invasion into the perineural space[15]. Clinically, high peritumoral β2-AR expression correlates with shortened survival, chemoresistance, and metastasis[16]. These findings support sympathetic nerves as a major driver of PNI. Parasympathetic signaling is bidirectional. Activation of CHRM1 inhibits MAPK/epidermal growth factor receptor pathways, thereby suppressing tumor growth and stemness[17]. However, muscarinic agonists in patients with resectable PDAC, although tolerated, modulate circulating immune markers such as interleukin-18[18]. Sensory nerves appear predominantly pro-tumor. Glutamate released by sensory nerves activates N-methyl-D-aspartate receptors, promoting PNI[19]. At the same time, substance P promotes crosstalk between tumor cells and Schwann cells[20]. Sensory nerve ablation prevents PNI, delays pancreatic intraepithelial neoplasia formation, and improves survival[21]. Sensory neurons and neuroendocrine cells can also promote tumorigenesis via neuronal crosstalk in PanIN lesions[22]. These findings position sensory nerves as a relatively consistent pro-tumor axis, although their contribution may vary by stage. The enteric nervous system contributes primarily by regulating the immune microenvironment. Enteric neurons extensively crosstalk with macrophages and T cells, and disruption of this balance may promote immune evasion[23]. Enteric glial cells can acquire a pro-tumor phenotype in the tumor microenvironment and regulate intestinal stem cells and tumor cells[24]. Enteric contributions remain less defined than sympathetic, parasympathetic, or sensory signaling and should not be assumed to mirror them. Among these pathways, sympathetic nerves have become the primary target for PNI intervention because their signaling axis combines clear driving efficacy with clinical intervenability.

CAFs as the core stromal effector cells of the autonomic nerve-tumor feedback loop model

CAFs orchestrate multiple stroma-dominated pathological events, including ECM deposition, interstitial contraction, and the construction of perineural ecological niches during PDAC progression. Tumor cells residing in nerve-adjacent regions are persistently exposed to integrated mechanical stimuli derived from ECM stiffness, perineural spatial confinement, and stromal contraction. Non-invaded nerve bundles are frequently surrounded by tertiary lymphoid structures populated with terminally differentiated effector CD8+ T cells, B lymphocytes, and plasma cells, forming an anti-tumor immune-hot microenvironment with tumor-protective functions. In contrast, perineurally invasive foci are characterized by an immunosuppressive landscape enriched with regulatory T cells, NOD-like receptor family pyrin domain-containing protein 3-positive myeloid cells, and activated fibroblasts, which jointly dampen local anti-tumor immunity and facilitate perineural tumor spread[5]. Recent studies have demonstrated that matrix stiffness can induce epithelial-mesenchymal transition (EMT)-like changes in pancreatic cancer cells and confer chemoresistance, accompanied by cytoskeletal remodeling and the nuclear translocation of mechanosensitive transcriptional regulators[13,25].

Spatial transcriptomics has further uncovered that PNI corresponds to a spatially restricted, specialized perineural microenvironment. Nevertheless, spatial-omics-derived findings demonstrate only regional spatial correlations, rather than definitive causal evidence of tumor dissemination[5]. Sympathetic-driven CAF activation and ECM remodeling further construct a mechanically permissive niche for PNI. Activated CAFs secrete structural matrix proteins and matrix-remodeling enzymes to tune tissue stiffness, interstitial fluid pressure, and vascular permeability[26]. Within desmoplasia-dominant PDAC, subtle changes in CAF activation status are sufficient to alter tumor mechanical rigidity and to open invasive corridors for cancer cells[27]. Single-cell and spatial transcriptomic studies have revealed that heterogeneous CAF subpopulations, including inflammatory CAFs (iCAFs), myofibroblastic CAFs (myCAFs), and antigen-presenting CAFs, are associated with distinct stromal states and functions[10,28].

MyCAF may represent the major CAF population involved in sympathetic nerve recruitment. In pre-invasive pancreatic lesions, dense new neural innervation has been observed near myCAF, while transforming growth factor beta (TGF-β) produced during inflammation and tumor formation promotes myofibroblast generation. Meanwhile, myCAF secretes axon-guiding molecules that recruit sympathetic nerves, and fibroblast-specific α1-AR signaling further promotes pancreatic inflammation and tumor progression[8]. These findings support a feedforward mechanism in which myCAF attracts sympathetic nerves, which in turn further activate these cells[8]. By contrast, iCAF and myCAF exhibit distinct spatial distributions and functional properties, and IL-1-induced JAK/STAT signaling promotes the iCAF program, whereas TGF-β drives myofibroblastic features[9,10]. Thus, these CAF subsets may respond differently to local inflammatory, neural, and mechanical cues and may exert divergent effects on PDAC biology. Therefore, sympathetic signals may integrate with, rather than act through, inflammatory and mechanical cues to regulate CAF functional states. Future studies should systematically compare the functional diversity of iCAF, myCAF, and apCAF; determine which CAF populations preferentially mediate sympathetic nerve recruitment; and define the cell-type-specific distribution and functional contribution of ARs within CAFs, tumor cells, and immune cells.

Sympathetic nerve-CAF feedback loop model establishes the basis for neural plasticity, reprogramming, and stromal remodeling in the PDAC microenvironment

Neural plasticity in PDAC comprises structural remodeling of the tumor-associated neural network. It also comprises sustained functional and transcriptional reprogramming of neurons and Schwann cells. Neural plasticity in PDAC is defined as maladaptive structural and functional reorganization of the tumor neural network, encompassing increased neural density and axonogenesis[29], architectural remodeling driven by Schwann cell transdifferentiation[30], and hyperexcitability via upregulated Transient receptor potential vanilloid 1 channels, along with aberrant neuro-glial-cancer connectivity[31]. Neural reprogramming denotes sustained transcriptional rewiring, exemplified by the activation of Activating Transcription Factor 3/c-JUN. This rewiring is coupled with a durable metabolic shift. Together, these changes impose a pro-neoplastic phenotype[30,32]. These neural changes may affect PDAC through several mechanisms. First, they accelerate tumor growth via NGF/brain-derived neurotrophic factor (BDNF) and NE-driven MAPK/PI3K signaling[33,34]. Second, it promotes PNI by establishing low-resistance routes and generating chemotactic C-X-C Motif Chemokine Ligand 12 (CXCL12)/Glial Cell Line-Derived Neurotrophic Factor (GDNF) gradients that guide cancer cells along nerves[32,35]. Third, it generates severe refractory pain through hyperexcitability and Substance P/Calcitonin Gene-Related Peptide (CGRP)-mediated peripheral and central sensitization[33]. Fourth, it sustains post-resection recurrence by upregulating ABC transporters (conferring chemoresistance) and maintaining cancer stem cells[36,37]. In addition, exuberant regenerative sprouting can re-establish a permissive niche. This may lead to relapse even after margin-negative resection[30,34]. Collectively, neural plasticity and reprogramming appear to be more than passive bystanders but are associated with PDAC progression, pain, and therapeutic failure.

Multiple CAF-derived signals mediate neural structural remodeling. It has been demonstrated that CAF-derived slit guidance ligand 2 increases dorsal root ganglion neuronal axon growth and Schwann cell migration/proliferation by modulating N-cadherin/β-catenin signaling, thereby participating in PDAC-associated neural remodeling[38]. Stromal leukemia inhibitory factor enhances neural remodeling and promotes tumor invasion[39]. CAF-derived extracellular vesicles (EVs) carrying PNI-associated transcripts drive neural remodeling through the PNI-associated transcript-Y-box binding protein-1 axis and influence neuronal epigenetic and transcriptomic reprogramming[40]. CAF-derived circular RNA KLHL24 (circKLHL24) drives PNI through dual regulation of the SEC31 homolog A-CXCL12 signaling axis, and targeting circKLHL24 or neutralizing CXCL12 suppresses tumor invasion and neuronal recruitment[41]. The stromal output of CAFs provides both physical and biochemical substrates for neural infiltration. MyCAF synthesizes and secretes large quantities of ECM components, including collagen and fibronectin, and mediates collagen crosslinking via crosslinking enzymes, leading to markedly increased stromal stiffness[27]. Elevated ECM density and stromal pressure compress blood vessels and alter vascular permeability, collectively creating a microenvironment conducive to nerve fiber invasion. Simultaneously, the dense fibrotic stroma induces immune exclusion through physical barriers and immunomodulation, while impairing the efficacy of chemotherapeutic agents and immunosuppressants, thereby resulting in therapeutic resistance[8,27]. These stromal alterations not only provide structural scaffolds for the growth of sympathetic nerves but also, through myCAF-mediated secretion of multiple axon guidance molecules, further chemoattract nerve fibers toward tumor lesions, thereby tightly coupling matrix remodeling with neural recruitment[8].

Taking NE-AR signaling as a starting point, multiple cell types in the pancreatic cancer microenvironment exhibit differential expression profiles. In CAFs, α1-AR is expressed in both murine models and human specimens of pancreatitis and PDAC, with significant upregulation under inflammatory and neoplastic conditions. NE induces calcium influx and cellular contraction in fibroblasts through α1-AR and downstream Gαq signaling[8]. In tumor tissues, β2-AR is expressed in multiple human PDAC cell lines, such as MiaPaCa-2 and BxPC-3. NE activates β2-AR to promote cell proliferation via the cAMP/PKA/STAT3 pathway, drives tumor growth and invasion through Poly(rC) binding protein 2-dependent upregulation of c-Myc, and enhances Aldo-keto reductase family 1 member B1 expression via the extracellular signal-regulated kinase 1/2 pathway[6,15,33]. At the immune cell level, β2-AR is broadly distributed across subsets, including CD8+ T cells, macrophages, and myeloid-derived suppressor cells (MDSCs). NE-β2-AR signaling directly induces programmed cell death protein 1 expression on CD8+ T cells while suppressing interleukin-2 and interferon gamma secretion, promotes macrophage polarization toward an immunosuppressive phenotype, and potentiates MDSC suppressive function through enhanced fatty acid oxidation[42].

Taken together, reprogrammed sympathetic nerves are associated with sustained neural fiber recruitment, enhanced adrenergic output, reprogramming of CAF states, and ECM remodeling. These features may co-occur and together appear compatible with a self-sustaining reinforcement-like loop (Table 1). Enhanced adrenergic output is one of the components associated with this loop model.

Table 1 Key evidence supporting the sympathetic nerve-cancer-associated fibroblast feedback loop model in pancreatic ductal adenocarcinoma.
Level of evidence Support
Evidence type
Experimental model
Directness of evidence
Cell
Receptor/signals
Interventions
Outcomes
Stromal/neural output
Unresolved question
Ref.
EstablishedA/B/C/DKPC mice/human PDAC tissueDirectUnclearβ2-ARTrk inhibitor and gemcitabine/Nonselective β-BlockerSurvival of PDAC mice and patients/tumor sizePancreatic nerve densityβ2-AR expression differs among CAFs and tumors[6]
EstablishedA/B/C/DGenetic sympathectomy KPC mice/human PDAC tissueDirectiCAF/ECMIL-6/JAK/STAT3Diphtheria toxin-inducible sympathectomyNeuro-associated survival trends in patientsAxon extensionUnderestimate the extent of bidirectional transcriptional regulation[7]
EstablishedB/C/DOrthotopic Transplantation Mouse Models/KPC mice/human PDAC tissueDirectmyCAFTGFβ1/SEMA7A; α1-AR/ERK, CREBChemical Sympathectomy/conditional Gαq-coupled hM3Dq designer receptor exclusively activated by designer drugsFibrosis and neoplastic expansionRecruitment of sympathetic nervesRequires further validation in patient-derived systems before translation to human PDAC[8]
Partially supportedC/DPancreatic cancer cells invade the sciatic nerveIndirectPancreatic cancer cellsNE/STAT3/NGF/MMP2/MMP9Block β-adrenergic receptors/block protein kinase ANeural invasionPancreatic cancer cell migration, invasion, and neural invasionExamine the clinical relevance[15]
Autonomic neural reprogramming drives an actively regulated metastatic process in PDAC

Recent studies provide increasingly strong evidence that neuroplasticity in PDAC and bidirectional crosstalk between sympathetic nerves and CAFs promote local stromal remodeling and primary tumor growth[4,7,8,43]. Direct mechanistic evidence also indicates that sympathetic signaling can facilitate PNI, although this evidence largely derives from earlier preclinical studies[15]. Although neural recruitment or broad neuronal inhibition has been linked to tumor dissemination or metastatic progression in selected models[44-46], a complete causal chain linking local sympathetic neurostromal remodeling to spontaneous distant metastatic dissemination has yet to be established. Moreover, clinical evidence that modulation of autonomic signaling can reproducibly reverse neural tumor-promoting programs remains limited and inconsistent (Table 2). Future translational investigations are therefore required to bridge this local-to-systemic gap and validate whether targeting autonomic-CAF signaling can interrupt metastatic cascades and yield durable clinical benefits for PDAC patients.

Table 2 Key evidence linking the sympathetic nerves-cancer-associated fibroblasts feedback loop model to neural invasion and metastatic progression in pancreatic ductal adenocarcinoma.
Level of evidence support
Evidence type
Experimental model
Directness of evidence
Cell
Receptor/signals
Interventions
Main conclusion
Limitations
Ref.
Partially supportedBHuman PDAC tissueIndirectmyCAFTGF-β/Enrichment of inflammatory NLRP3 TAMs and myCAFs around invaded nerves promotes tumor cell migration and correlates with poor survivalThe study does not establish a prospective prediction of distant metastasis[5]
EstablishedA/B/C/DGenetic sympathectomy KPC mice/human PDAC tissueDirectCAFSEMA3CDiphtheria toxin-inducible sympathectomySEMA3C expression in response to sympathetic signaling enhances PDAC EMTDirect validation of metastatic endpoints in human-derived models remains limited[7]
EstablishedB/C/DKPC mice crossed with ANXA2-knockout mice/human PDAC tissueIndirectPancreatic ductal adenocarcinoma cells/neuronsSEMA3D/ANXA2SEMA3D or ANXA2 was knocked downKnockdown of SEMA3D and loss of neural PLXND1 reduce the innervation of orthotopic PDACs and metastasis in miceIt remains unclear whether SEMA3D is predominantly secreted by myCAFs or malignant epithelial cells in vivo[46]
Partially supportedA/B/C/DSerum and tissue from human PDAC patients/mouse models of PDACIndirectPDAC stromal cellsLIF/LIFR/GP130Injection of LIF-blocking antibodyLIF titers positively correlated with intratumoral nerve density in serum from human PDAC patients and mouse models of PDACThe specific neural and stromal cell subtypes were not specified[39]
KEY SIGNALING PATHWAYS OF AUTONOMIC NEURAL REPROGRAMMING IN PDAC
PIEZO1 links the nerve-associated microenvironment to PDAC PNI and dissemination

PIEZO1 and PIEZO2 were initially identified as essential components of mechanically activated cation channels, thereby establishing Piezo channels as central mediators of force sensing in mammalian cells[47]. The gastrointestinal tract is continuously exposed to mechanical forces generated by luminal distension and peristalsis[48]. Mechanosensitive Piezo channels are expressed in a subset of gut epithelial enterochromaffin cells and in cholinergic enteric neurons, where PIEZO2 and PIEZO1, respectively, contribute to mechanically evoked serotonin release and intestinal motility[48,49].

In this context, PIEZO1 has emerged as a key mechanotransducer in PDAC, where its expression is markedly upregulated and closely correlated with PNI[12]. Direct evidence for PIEZO1 involvement in PDAC neural invasion derives from multiple experimental modalities. Spatial transcriptomic analysis of human PDAC specimens revealed that PIEZO1 expression was significantly higher in nerve-infiltrating peritumoral regions than in non-nerve-infiltrating tumor regions, exhibiting a spatial gradient that gradually declined from tumor regions proximal to nerves toward distal tumor sites. Immunohistochemical and immunofluorescence assays on tissue sections further validated PIEZO1 enrichment in PNI foci and its colocalization with perineural cancer cells. In vitro functional assays using PDAC cell lines demonstrated that pharmacological activation of PIEZO1 potentiated cell migration, invasive capacity, neurotrophic factor expression, neural adhesion, and neurotropism, whereas PIEZO1 inhibition or genetic knockdown attenuated these phenotypes. Mechanistically, PIEZO1 drives EMT via activation of the Hippo signaling pathway, thereby facilitating active neural invasion by cancer cells[12].

Two critical questions arise regarding the specificity and translational relevance of these findings. First, whether PIEZO1 activation is specifically triggered in nerve-adjacent tumor cells or represents a generalized response to microenvironmental stiffness remains incompletely addressed. The spatial gradient of PIEZO1 expression, with higher near nerves and lower in distal regions, suggests a local enrichment that may reflect the unique mechanical milieu created by nerve-tumor interactions, rather than a uniform stiffness-sensing response. Whether the therapeutic effects of PIEZO1 inhibition have been replicated in clinically relevant models, such as patient-derived organoids or patient-derived xenografts, remains to be established. The in vivo evidence reported to date derives from a sciatic nerve infiltration model employing pancreatic cancer cells. While valuable for investigating PNI, this model does not fully reproduce the native pancreatic tumor microenvironment or the spontaneous progression of PDAC. Thus, although PIEZO1 has been demonstrated to regulate additional malignant phenotypes in PDAC including matrix stiffness-induced glycolytic reprogramming and gemcitabine resistance in three-dimensional culture models[13], as well as tumor-promoting functions in pancreatic stellate cells and oncogenic activity in PDAC cell lines[50,51], the specificity of nerve-adjacent PIEZO1 activation and the generalizability of its inhibition across clinically relevant preclinical models remain areas requiring further investigation.

Collectively, PIEZO1 is a mechanosensor localized in perineural regions, and its spatial distribution and functional properties are consistent with a role in sensing dynamic mechanical cues within the autonomic nerve-rich PNI microenvironment. These cues are associated with cancer cell behavioral programs characterized by neural invasion. By modulating multiple malignant phenotypes of tumor cells and stromal cells in the tumor microenvironment, PIEZO1 is associated with PDAC progression and metastasis.

The PIEZO1-YAP1 axis couples nerve-associated mechanics to tumor–nerve interactions and invasive plasticity

PIEZO1 has been linked to stiffness-induced chemoresistance through glycolytic reprogramming[13,51]. YAP1 is a major nuclear effector of mechanotransduction, converting matrix stiffness, cell spreading, and cytoskeletal tension into transcriptional programs that regulate proliferation, survival, and lineage plasticity[14]. In PDAC, active YAP promotes cell motility, invasion, and anchorage-independent growth[52], and participates in tumor-stromal interactions by regulating pancreatic cancer cell invasion and pancreatic stellate cell activation[53].

These observations place YAP1 as a contributor to aggressive PDAC phenotypes. More directly, PIEZO1 is enriched in tumor cells adjacent to invaded nerves. Its pharmacological activation increases YAP1 nuclear localization, neurotrophic factor expression, and neural invasion, whereas pathway inhibition attenuates these effects[12]. The PIEZO1-YAP1 axis may therefore provide a mechanistic rationale for therapeutic exploration to limit neurotrophic and neuroinvasive phenotypes. However, this possibility currently rests on a single PDAC study and requires independent validation. Direct regulation of PIEZO1 gating by autonomic neurotransmission has not been demonstrated; it is also unclear whether the PIEZO1-YAP1 response is specific to nerve-adjacent tumor cells or represents a broader reaction to stromal stiffness. Collectively, these observations point toward a potential PIEZO1-YAP1 mechanotransductive link that may contribute to neurotrophic and neuroinvasive phenotypes in PDAC.

THERAPEUTIC POTENTIAL AND TRANSLATIONAL BARRIERS

Elucidating neural-tumour-cell feedback circuits is important for therapeutic development in PDAC. The cell type bearing the therapeutic target, reproducibility in relevant PDAC models, achievable spatial selectivity, expected biological endpoint, normal-tissue tolerability, and availability of pharmacodynamic markers should serve as essential evaluation criteria. Applying these criteria to AR- and CAF-associated pathways, as well as to PIEZO1 and the YAP/TEAD, will be critical for determining their therapeutic potential[7,9,12].

Unexpected consequences of sympathetic nerve-CAF targeting and selective normalization

PDAC stromal studies demonstrate the risks of broad CAF depletion. Broad CAF targeting can impair wound repair and protective stroma. Engineered EVs can be ligand-directed to reprogram CAFs and enhance therapeutic efficacy in preclinical pancreatic cancer models[54]. Genetic depletion of alpha-smooth-muscle-actin (alpha-SMA)-positive myofibroblasts produced poorly differentiated, hypoxic, immunosuppressed tumors and shortened survival in mice[55]. Shh deletion or Smoothened inhibition reduced the stroma and accelerated tumor growth and vascularity[56]. Deletion of type I collagen from alpha-SMA-positive myofibroblasts also increased immunosuppression and disease progression[57]. These experiments reveal protective functions within heterogeneous stromal compartments. Broad depletion can remove physical containment, vascular control, and immune-supportive functions. Alpha-SMA, Fibroblast Activation Protein (FAP), Leucine-Rich Repeat-Containing Protein (LRRC15), and broad transcriptomic clusters lack sufficient specificity for the fibroblast program that recruits nerves, stiffens the perineural matrix, and supports invasion. MyCAF and iCAF programs occupy distinct spatial niches and arise from competing cytokine signals[9,10]. Their states are plastic, and fibroblast diversity extends beyond these two programs. Single-cell lineage studies identify fibroblast populations that support anti-tumor immunity[58]. Recent analysis of FAP-positive cells also identified an interferon-response CAF state with tumor-restraining properties[59]. Stromal reprogramming is experimentally feasible. Vitamin D receptor activation can shift stellate cells towards quiescence and improve gemcitabine delivery in PDAC models[60].

Neural interventions offer upstream approaches to CAF targeting. Tumor-cell beta-2 AR blockade or Trk inhibition improved gemcitabine responses in Kirsten rat sarcoma viral oncogene homolog/Transformation related protein 53 (Kras/Trp53)-driven KPC models[6]. Recent work identifies alpha-1 adrenergic signaling and neuroplastic cues in fibroblasts and myofibroblasts[8]. Human beta-blocker evidence remains hypothesis-generating[61]. Retrospective survival associations are susceptible to confounding[62].

Clinical development now requires a defined CAF state linked to neural recruitment. Development of a selective neural-stromal strategy begins with a reproducible definition of the pathogenic fibroblast state. Human PDAC samples should be used to localize the candidate population to invaded or nerve-reactive regions. The cells should express the relevant AR or neural response program. Reversible, cell-specific perturbation should then be tested in models with intact immunity and innervation. A successful intervention should reduce axonal recruitment, pathological mechanics, PNI, and spontaneous metastasis. Analyses should account for spatial location, disease stage, sex, treatment history, and state transitions[5,7,8,11].

Lack of evidence for neural modulation of PIEZO1 and insufficient targeting specificity toward PIEZO1

Yoda1 is a chemical PIEZO1 agonist. GsMTx4 modifies channel gating and inhibits PIEZO1 along with other mechanosensitive currents[63,64]. Yoda1-induced PIEZO1 activation promoted cadherin switching, migration, and invasion, and upregulated NGF, BDNF, and GDNF; GsMTx4-mediated inhibition attenuated these effects. Verteporfin, a YAP1 inhibitor, suppressed PIEZO1-driven neural invasion. Reviews of PIEZO1 pharmacology identify limitations in selectivity, potency, stability, exposure, and cross-tissue interpretation[65,66]. Verteporfin provided early evidence that pharmacological disruption of the TEAD-YAP association is feasible[67]. However, its pleiotropic photosensitizing and YAP-independent effects limit its use as a selective systemic YAP inhibitor[68]. TEAD palmitoylation inhibitors with greater selectivity have entered early clinical testing in other solid tumors[69]. Efficacy in PDAC and PNI remains untested. Systemic PIEZO1 inhibition may disrupt physiological mechanosensing in blood cells, vasculature, lymphatics, and other tissues. Systemic YAP/TEAD inhibition may affect regenerative and homeostatic programs. A therapeutic window may require control of payload, target cell, anatomical region, and treatment interval. For nerve-adjacent targets, drug exposure should be measured directly within the perineural niche[55,65,66].

Existing delivery platforms provide useful precedents. The tumor-penetrating peptide iRGD increased vascular and tissue permeability in tumor models through integrin- and neuropilin-1-dependent mechanisms[70]. Certepetide also targets integrins and neuropilin. Its combination with nab-paclitaxel and gemcitabine entered a first-in-human phase 1 study in PDAC[71]. This study supports the clinical feasibility of penetration-enhancing strategies. Their development requires explicit identification of the target cell and evidence of the stage. Such delivery must also spare normal pancreatic nerves, vessels, immune cells, and mechanically responsive tissues. Local injection, image-guided administration, activatable prodrugs, nanoparticles, peptides, and EVs should advance[54,71].

Biomarkers, patient selection, and combinations

Biomarker development should begin with a defined context of use. Histological PNI burden and nerve density are prognostic indicators because they reflect aggressive neural involvement[2,3]. Their ability to predict response to a specific neural or mechanotransduction therapy remains unestablished. Peritumoral β2-AR immunoreactivity correlates with clinical outcome in retrospective studies[16]. Receptor dependence and treatment benefit require prospective testing. Spatial PIEZO1 enrichment, nuclear YAP1, nerve-reactive malignant states, endoneurial fibroblasts, Schwann-cell states, and local immune architecture are more closely aligned with the proposed mechanism[5,12]. These features may serve as predictive or pharmacodynamic biomarkers. A practical biomarker program can combine tissue, imaging, and circulating measurements. Each measurement should retain its specific context of use. Pretreatment biopsies can quantify nerve density, PNI architecture, receptor-bearing cell types, CAF states, PIEZO1 localization, nuclear YAP1, collagen organization, and immune exclusion. Serial imaging can track stromal change. Fibroblast activation protein inhibitor-positron emission tomography detects FAP-associated biology in PDAC and has been explored for staging and response assessment[72,73]. FAPI uptake has limited specificity for neuroactivating CAFs and PIEZO1-active perineural niches. Its role in patient selection and pharmacodynamic monitoring requires prospective validation.

Combination therapy should address experimentally established and non-redundant resistance mechanisms. Pharmacological denervation can remodel the immune microenvironment and improve checkpoint blockade activity in PDAC models[4]. Tumor-cell β2-AR or Trk inhibition has been combined with gemcitabine[6]. Interruption of FAP-positive-CAF-derived CXCL12 releases T-cell exclusion and enhances anti-PD-L1 activity in mice[74]. These studies support mechanism-defined combination experiments. PIEZO1 and TEAD combinations require their own causal evidence. Combination studies should include factorial single-agent controls, sequence and dose optimization, cell-specific target engagement, rescue tests, immune and mechanical endpoints, and assessment of overlapping cardiovascular, neurological, stromal, and hematological toxicity. An integrated causal study is the most informative next step. The study should use an orthotopic or genetically engineered PDAC model with intact immunity and spontaneous dissemination. Autonomic input, the receptor-bearing CAF state, tumor-cell PIEZO1, and YAP/TEAD should be perturbed separately and in sequence. The same animals should undergo calibrated measurement of regional matrix mechanics, spatial cell states, PNI, liver and lung metastasis, treatment response, and organ-specific toxicity. Parallel human tissue and organoid-neuron-CAF systems should be used to test the conservation of cell state and pharmacodynamic markers[4,5,7,12].

Patient selection and context of use

The target patient population and clinical context must be explicitly defined for any proposed neural or mechanotransduction therapy. Resectable, locally advanced, and metastatic PDAC represent distinct clinical scenarios with different tumor microenvironments, immune contexts, and therapeutic goals. A neural-stromal targeting strategy may be most feasible in the neoadjuvant or adjuvant setting for resectable disease, where the tumor is accessible for spatial profiling, and the goal is to prevent local recurrence and distant dissemination. In metastatic disease, the priority shifts to systemic control, and the therapeutic window for neural modulation may be narrower. Biomarker-based patient selection strategies should be developed in parallel with therapeutic candidates, and the feasibility of implementing image-guided or spatial-omics-based biomarkers must be assessed in the context of available healthcare resources and infrastructure.

CONCLUSION

An integrated causal study is the most informative next step. The study should use an orthotopic or genetically engineered PDAC model with intact immunity and spontaneous dissemination. Autonomic input, the receptor-bearing CAF state, tumour-cell PIEZO1, and YAP/TEAD should be perturbed separately and in sequence. The same animals should undergo calibrated measurement of regional matrix mechanics, spatial cell states, PNI, liver and lung metastasis, treatment response, and organ-specific toxicity. Rescue experiments should establish necessity and pathway order. Parallel human tissue and organoid-neuron-CAF systems should test conservation of the cell state and pharmacodynamic markers. Prespecified falsification criteria should address three outcomes. Dissociation of PNI from CAF mechanics and spontaneous metastasis would weaken the local-to-systemic link. Equivalent effects of PIEZO1 loss in nerve-adjacent and nerve-distant cells would weaken nerve specificity. Failure of YAP rescue to restore the phenotype would weaken the proposed pathway order. Clinical development requires a reproducible exposure-target-engagement-mechanism-outcome relationship, a feasible spatial delivery strategy, and an analytically validated biomarker[4,5,7,12].

References
1.  Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008-2020.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2265]  [Cited by in RCA: 2004]  [Article Influence: 334.0]  [Reference Citation Analysis (21)]
2.  Schorn S, Demir IE, Haller B, Scheufele F, Reyes CM, Tieftrunk E, Sargut M, Goess R, Friess H, Ceyhan GO. The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Surg Oncol. 2017;26:105-115.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 129]  [Cited by in RCA: 120]  [Article Influence: 13.3]  [Reference Citation Analysis (6)]
3.  Nozzoli F, Catalano M, Messerini L, Cianchi F, Nassini R, De Logu F, Iannone LF, Ugolini F, Simi S, Massi D, Geppetti P, Roviello G. Perineural invasion score system and clinical outcomes in resected pancreatic cancer patients. Pancreatology. 2024;24:553-561.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 10]  [Reference Citation Analysis (0)]
4.  Thiel V, Renders S, Panten J, Dross N, Bauer K, Azorin D, Henriques V, Vogel V, Klein C, Leppä AM, Barriuso Ortega I, Schwickert J, Ourailidis I, Mochayedi J, Mallm JP, Müller-Tidow C, Monyer H, Neoptolemos J, Hackert T, Stegle O, Odom DT, Offringa R, Stenzinger A, Winkler F, Sprick M, Trumpp A. Characterization of single neurons reprogrammed by pancreatic cancer. Nature. 2025;640:1042-1051.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 87]  [Cited by in RCA: 111]  [Article Influence: 111.0]  [Reference Citation Analysis (0)]
5.  Chen MM, Gao Q, Ning H, Chen K, Gao Y, Yu M, Liu CQ, Zhou W, Pan J, Wei L, Dou W, Zhang D, Zhu L, Zhang Q, Chen R, Zhang Z. Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer. Cancer Cell. 2025;43:1656-1676.e10.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 43]  [Cited by in RCA: 95]  [Article Influence: 95.0]  [Reference Citation Analysis (3)]
6.  Renz BW, Takahashi R, Tanaka T, Macchini M, Hayakawa Y, Dantes Z, Maurer HC, Chen X, Jiang Z, Westphalen CB, Ilmer M, Valenti G, Mohanta SK, Habenicht AJR, Middelhoff M, Chu T, Nagar K, Tailor Y, Casadei R, Di Marco M, Kleespies A, Friedman RA, Remotti H, Reichert M, Worthley DL, Neumann J, Werner J, Iuga AC, Olive KP, Wang TC. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Cancer Cell. 2018;33:75-90.e7.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 242]  [Cited by in RCA: 428]  [Article Influence: 53.5]  [Reference Citation Analysis (0)]
7.  Sattler AL, Diba P, Hawthorne K, Pelz C, Grieco J, Korzun T, Chong B, Kuykendall MJ, Sears RC, Marks DL, Sherman MH, Zimmers TA, Eksi SE. Sympathetic nerve-fibroblast crosstalk drives nerve injury, fibroblast activation, and matrix remodeling in pancreatic cancer. JCI Insight. 2026;11:e192814.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 11]  [Cited by in RCA: 6]  [Article Influence: 6.0]  [Reference Citation Analysis (1)]
8.  Nigri J, Lan W, Fung ML, Kayser C, Deschênes A, Hinds J, Kaushalya S, Pawlak SA, Thalappillil JS, Nadella S, Hilmi M, Park W, Kappagantula R, Park Y, Zhao Z, Preall J, Iacobuzio-Donahue CA, Tracey KJ, Borniger JC, Tuveson DA. Myofibroblasts Induce Neuroplasticity to Promote Pancreatic Inflammation and Cancer Progression. Cancer Discov. 2026;16:1014-1034.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 12]  [Cited by in RCA: 10]  [Article Influence: 10.0]  [Reference Citation Analysis (0)]
9.  Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, Preall J, Tuveson DA. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancer Discov. 2019;9:282-301.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1163]  [Cited by in RCA: 1134]  [Article Influence: 162.0]  [Reference Citation Analysis (4)]
10.  Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriac H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson DA. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214:579-596.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2219]  [Cited by in RCA: 2110]  [Article Influence: 234.4]  [Reference Citation Analysis (10)]
11.  Xue M, Zhu Y, Jiang Y, Han L, Shi M, Su R, Wang L, Xiong C, Wang C, Wang T, Deng S, Wu D, Cao Y, Dong L, Bai F, Zhao S, Deng X, Peng C, Li H, Chen J, Shen B, Jiang L, Chen H. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. Nat Commun. 2023;14:4600.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 58]  [Cited by in RCA: 102]  [Article Influence: 34.0]  [Reference Citation Analysis (0)]
12.  Li J, Liu Q, Xu R, Tang J, Wang L, Zheng Y, Weng S, Gao F. PIEZO1 enhances pancreatic cancer neurotropism. Cancer Cell Int. 2026;26:152.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 3]  [Reference Citation Analysis (1)]
13.  Pan H, Zhang X, Zhu S, Zhu B, Wu D, Yan J, Guan X, Huang Y, Zhao Y, Yang Y, Guo Y. Piezo1 Mediates Glycolysis-Boosted Pancreatic Ductal Adenocarcinoma Chemoresistance within a Biomimetic Three-Dimensional Matrix Stiffness. ACS Biomater Sci Eng. 2024;10:7632-7646.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 8]  [Cited by in RCA: 16]  [Article Influence: 8.0]  [Reference Citation Analysis (0)]
14.  Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, Elvassore N, Piccolo S. Role of YAP/TAZ in mechanotransduction. Nature. 2011;474:179-183.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 5248]  [Cited by in RCA: 4777]  [Article Influence: 318.5]  [Reference Citation Analysis (9)]
15.  Guo K, Ma Q, Li J, Wang Z, Shan T, Li W, Xu Q, Xie K. Interaction of the sympathetic nerve with pancreatic cancer cells promotes perineural invasion through the activation of STAT3 signaling. Mol Cancer Ther. 2013;12:264-273.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 48]  [Cited by in RCA: 98]  [Article Influence: 7.5]  [Reference Citation Analysis (0)]
16.  Târtea EA, Petrescu M, Udriștoiu I, Gheorman V, Biciușcă V, Petrescu AR, Ciurea AM, Vere CC. Clinical Outcomes Depending on Sympathetic Innervation in Pancreatic Cancer. Cancers (Basel). 2023;15:3040.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 7]  [Reference Citation Analysis (0)]
17.  Renz BW, Tanaka T, Sunagawa M, Takahashi R, Jiang Z, Macchini M, Dantes Z, Valenti G, White RA, Middelhoff MA, Ilmer M, Oberstein PE, Angele MK, Deng H, Hayakawa Y, Westphalen CB, Werner J, Remotti H, Reichert M, Tailor YH, Nagar K, Friedman RA, Iuga AC, Olive KP, Wang TC. Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness. Cancer Discov. 2018;8:1458-1473.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 342]  [Cited by in RCA: 284]  [Article Influence: 35.5]  [Reference Citation Analysis (0)]
18.  White RA, Mezzano-Robinson V, Shi Q, Kuriakose N, Schrope B, Kluger MD, Sugahara K, Chabot J, Manji G, Oberstein P, Remotti H, Wang TC, Bates SE. A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery. Oncologist. 2025;30:oyaf162.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 6]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
19.  Li F, He C, Yao H, Zhao Y, Ye X, Zhou S, Zou J, Li Y, Li J, Chen S, Han F, Huang K, Lian G, Chen S. Glutamate from nerve cells promotes perineural invasion in pancreatic cancer by regulating tumor glycolysis through HK2 mRNA-m6A modification. Pharmacol Res. 2023;187:106555.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 55]  [Reference Citation Analysis (2)]
20.  Mardelle U, Bretaud N, Daher C, Feuillet V. From pain to tumor immunity: influence of peripheral sensory neurons in cancer. Front Immunol. 2024;15:1335387.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 49]  [Reference Citation Analysis (1)]
21.  Saloman JL, Albers KM, Li D, Hartman DJ, Crawford HC, Muha EA, Rhim AD, Davis BM. Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of cancer. Proc Natl Acad Sci U S A. 2016;113:3078-3083.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 355]  [Cited by in RCA: 348]  [Article Influence: 34.8]  [Reference Citation Analysis (25)]
22.  Sinha S, Fu YY, Grimont A, Ketcham M, Lafaro K, Saglimbeni JA, Askan G, Bailey JM, Melchor JP, Zhong Y, Joo MG, Grbovic-Huezo O, Yang IH, Basturk O, Baker L, Park Y, Kurtz RC, Tuveson D, Leach SD, Pasricha PJ. PanIN Neuroendocrine Cells Promote Tumorigenesis via Neuronal Cross-talk. Cancer Res. 2017;77:1868-1879.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 9]  [Cited by in RCA: 52]  [Article Influence: 5.8]  [Reference Citation Analysis (0)]
23.  Wang X, Ding C, Li HB. The crosstalk between enteric nervous system and immune system in intestinal development, homeostasis and diseases. Sci China Life Sci. 2024;67:41-50.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 6]  [Cited by in RCA: 23]  [Article Influence: 11.5]  [Reference Citation Analysis (0)]
24.  Mariant CL, Bacola G, Van Landeghem L. Mini-Review: Enteric glia of the tumor microenvironment: An affair of corruption. Neurosci Lett. 2023;814:137416.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 6]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
25.  Rice AJ, Cortes E, Lachowski D, Cheung BCH, Karim SA, Morton JP, Del Río Hernández A. Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis. 2017;6:e352.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 236]  [Cited by in RCA: 446]  [Article Influence: 49.6]  [Reference Citation Analysis (0)]
26.  Kugeratski FG, Kay EJ, Zanivan S. Cancer-associated fibroblasts as mediators of tissue microenvironment remodeling in cancer. Curr Opin Cell Biol. 2025;96:102567.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 4]  [Reference Citation Analysis (0)]
27.  Yang A, Gu C, Liu Y, Luo B, Zeng Y, Zhou M, Li C, Pan C, Wu L, Hu Z, Zhang X, Gao F, Shi Y. ITGB5-mediated biomechanical regulation in pancreatic ductal adenocarcinoma stroma impacts tumor progression and prognosis. J Transl Med. 2025;23:1150.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2]  [Cited by in RCA: 3]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
28.  Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, Sivajothi S, Armstrong TD, Engle DD, Yu KH, Hao Y, Wolfgang CL, Park Y, Preall J, Jaffee EM, Califano A, Robson P, Tuveson DA. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discov. 2019;9:1102-1123.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1841]  [Cited by in RCA: 1791]  [Article Influence: 255.9]  [Reference Citation Analysis (16)]
29.  Genova E, Montrone M, Rangaswamy U, Diversi F, Schiavo I, Ferrarini D, Di Florio R, Longo I, Coscia M, Zamboni N, Demontis G, Veghini L, Corbo V, Sanges R, Heppenstall P. Deciphering transcriptional plasticity in pancreatic ductal adenocarcinoma reveals alterations in sensory neuron innervation. Mol Oncol. 2026;20:1726-1741.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 1]  [Reference Citation Analysis (1)]
30.  Rangel-Sosa MM, Mann F, Chauvet S. Pancreatic Schwann cell reprogramming supports cancer-associated neuronal remodeling. Glia. 2024;72:1840-1861.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 19]  [Cited by in RCA: 26]  [Article Influence: 13.0]  [Reference Citation Analysis (0)]
31.  Ni B, Yin Y, Li Z, Wang J, Wang X, Wang K. Crosstalk Between Peripheral Innervation and Pancreatic Ductal Adenocarcinoma. Neurosci Bull. 2023;39:1717-1731.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2]  [Cited by in RCA: 21]  [Article Influence: 7.0]  [Reference Citation Analysis (1)]
32.  He Y, Chen Z, Yang L, Qiao S, Su Z, Ding F, Ding F, Xin F, Xiang S, Lyu A, Li F. The supporting role of Schwann cells in perineural invasion of pancreatic ductal adenocarcinoma. Front Pharmacol. 2025;16:1540027.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 6]  [Reference Citation Analysis (0)]
33.  Crispim JG, Silva CNP, de Melo Rêgo MJB, da Rosa MM. Interactions between the nervous system and PDAC progression: Regulatory mechanisms and therapeutic implications. Eur J Pharmacol. 2026;1021:178829.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 4]  [Reference Citation Analysis (0)]
34.  Cheng J, Wang R, Chen Y. Neuroimmune Interactions in Pancreatic Cancer. Biomedicines. 2025;13:609.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 5]  [Reference Citation Analysis (1)]
35.  Li J, Kang R, Tang D. Cellular and molecular mechanisms of perineural invasion of pancreatic ductal adenocarcinoma. Cancer Commun (Lond). 2021;41:642-660.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 106]  [Cited by in RCA: 116]  [Article Influence: 23.2]  [Reference Citation Analysis (1)]
36.  Vaskovich-Koubi D, Green Buzhor M, Krinsky A, Roth Y, Salomon K, Kleiner R, Sevostianov R, Hasin O, Khoury R, Satchi-Fainaro R. Patient-Derived 3D-Bioprinted Models of Pancreatic Cancer: Toward Personalized Therapy and Overcoming Tumor Microenvironment Challenges. Adv Drug Deliv Rev. 2025;225:115670.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2]  [Cited by in RCA: 8]  [Article Influence: 8.0]  [Reference Citation Analysis (0)]
37.  Pian LL, Song MH, Wang TF, Qi L, Peng TL, Xie KP. Identification and analysis of pancreatic intraepithelial neoplasia: opportunities and challenges. Front Endocrinol (Lausanne). 2024;15:1401829.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 9]  [Cited by in RCA: 11]  [Article Influence: 11.0]  [Reference Citation Analysis (0)]
38.  Secq V, Leca J, Bressy C, Guillaumond F, Skrobuk P, Nigri J, Lac S, Lavaut MN, Bui TT, Thakur AK, Callizot N, Steinschneider R, Berthezene P, Dusetti N, Ouaissi M, Moutardier V, Calvo E, Bousquet C, Garcia S, Bidaut G, Vasseur S, Iovanna JL, Tomasini R. Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling. Cell Death Dis. 2015;6:e1592.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 49]  [Cited by in RCA: 82]  [Article Influence: 7.5]  [Reference Citation Analysis (5)]
39.  Bressy C, Lac S, Nigri J, Leca J, Roques J, Lavaut MN, Secq V, Guillaumond F, Bui TT, Pietrasz D, Granjeaud S, Bachet JB, Ouaissi M, Iovanna J, Vasseur S, Tomasini R. LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. Cancer Res. 2018;78:909-921.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 55]  [Cited by in RCA: 94]  [Article Influence: 10.4]  [Reference Citation Analysis (3)]
40.  Zheng S, Hu C, Lin Q, Li T, Li G, Tian Q, Zhang X, Huang T, Ye Y, He R, Chen C, Zhou Y, Chen R. Extracellular vesicle-packaged PIAT from cancer-associated fibroblasts drives neural remodeling by mediating m5C modification in pancreatic cancer mouse models. Sci Transl Med. 2024;16:eadi0178.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 55]  [Reference Citation Analysis (0)]
41.  Li T, He R, Tian Q, Huang T, Jiang H, Chen H, Yuan Y, Jiang Y, Zheng S, Hu C, Li S, Li G, Chen R. Cancer-associated fibroblast-derived circKLHL24 drives perineural invasion in pancreatic cancer via dual regulation of the sec31a-CXCL12 axis. J Exp Clin Cancer Res. 2025;44:281.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 9]  [Reference Citation Analysis (0)]
42.  Zhang C, Guo X, Liu P, Wang Y, Zhang J, Li L, Wu K, Xiao J, Mei Q, Wang Z. The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities. J Hematol Oncol. 2025;18:93.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 13]  [Cited by in RCA: 28]  [Article Influence: 28.0]  [Reference Citation Analysis (0)]
43.  Chen Z, Zhou Y, Xue C, Zeng L, Deng S, Xu Z, Li M, Zhao H, He X, Liu S, Liu J, Liu S, Zhao S, Zhang S, Peng X, Wu X, Bai R, Zhuang L, Wu S, Zhang J, Lin D, Huang X, Zheng J. Psychological stress-induced ALKBH5 deficiency promotes tumour innervation and pancreatic cancer via extracellular vesicle transfer of RNA. Nat Cell Biol. 2025;27:1035-1047.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 38]  [Reference Citation Analysis (1)]
44.  Kobayashi H, Ochiai Y, Arai J, Hata M, Wu F, Sunagawa M, Iida T, Baba T, Malagola E, Tanaka T, Jiang Z, White RA, Zhi X, Qian J, Waterbury QT, Tu R, Zheng B, Zeng Y, Zheng H, Zhang P, Li S, Zamechek LB, LaBella JS, Sugie T, Enomoto A, Eltzschig HK, Palermo CF, Chio IIC, Olive KP, Wang TC. Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1. Cancer Res. 2026;86:1883-1901.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 6]  [Cited by in RCA: 7]  [Article Influence: 7.0]  [Reference Citation Analysis (0)]
45.  Wang Z, Wei J, Sun J, Li N, Liu J, Huang Y, Nie G, Li Y. Halting Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Neuron-Inhibitory Liposomes. Nano Lett. 2025;25:1964-1973.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 6]  [Reference Citation Analysis (0)]
46.  Jurcak NR, Rucki AA, Muth S, Thompson E, Sharma R, Ding D, Zhu Q, Eshleman JR, Anders RA, Jaffee EM, Fujiwara K, Zheng L. Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice. Gastroenterology. 2019;157:838-850.e6.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 98]  [Cited by in RCA: 171]  [Article Influence: 24.4]  [Reference Citation Analysis (6)]
47.  Coste B, Mathur J, Schmidt M, Earley TJ, Ranade S, Petrus MJ, Dubin AE, Patapoutian A. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science. 2010;330:55-60.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2492]  [Cited by in RCA: 2582]  [Article Influence: 161.4]  [Reference Citation Analysis (11)]
48.  Xie Z, Rose L, Feng J, Zhao Y, Lu Y, Kane H, Hibberd TJ, Hu X, Wang Z, Zang K, Yang X, Richardson Q, Othman R, Venezia O, Zhakyp A, Gao F, Abe N, Vigeland K, Wang H, Branch C, Duizer C, Deng L, Meng X, Zamidar L, Hauptschein M, Bergin R, Dong X, Chiu IM, Kim BS, Spencer NJ, Hu H, Jackson R. Enteric neuronal Piezo1 maintains mechanical and immunological homeostasis by sensing force. Cell. 2025;188:2417-2432.e19.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 37]  [Cited by in RCA: 53]  [Article Influence: 53.0]  [Reference Citation Analysis (0)]
49.  Alcaino C, Knutson KR, Treichel AJ, Yildiz G, Strege PR, Linden DR, Li JH, Leiter AB, Szurszewski JH, Farrugia G, Beyder A. A population of gut epithelial enterochromaffin cells is mechanosensitive and requires Piezo2 to convert force into serotonin release. Proc Natl Acad Sci U S A. 2018;115:E7632-E7641.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 247]  [Cited by in RCA: 226]  [Article Influence: 28.3]  [Reference Citation Analysis (0)]
50.  Romac JM, Swain SM, Mullappilly N, Bindhani B, Liddle RA. Loss of TRPV4 reduces pancreatic cancer growth and metastasis. JCI Insight. 2025;10:e196280.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 4]  [Cited by in RCA: 4]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
51.  Zhu Z, Li W, Gong M, Wang L, Yue Y, Qian W, Zhou C, Duan W, Han L, Li L, Wu Z, Ma Q, Lin M, Wang S, Wang Z. Piezo1 act as a potential oncogene in pancreatic cancer progression. Life Sci. 2022;310:121035.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 18]  [Reference Citation Analysis (0)]
52.  Yang S, Zhang L, Purohit V, Shukla SK, Chen X, Yu F, Fu K, Chen Y, Solheim J, Singh PK, Song W, Dong J. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget. 2015;6:36019-36031.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 73]  [Cited by in RCA: 89]  [Article Influence: 8.9]  [Reference Citation Analysis (0)]
53.  Jiang Z, Zhou C, Cheng L, Yan B, Chen K, Chen X, Zong L, Lei J, Duan W, Xu Q, Li X, Wang Z, Ma Q, Ma J. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. J Exp Clin Cancer Res. 2018;37:69.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 31]  [Cited by in RCA: 59]  [Article Influence: 7.4]  [Reference Citation Analysis (0)]
54.  Zhou P, Du X, Jia W, Feng K, Zhang Y. Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer. Signal Transduct Target Ther. 2024;9:151.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 63]  [Reference Citation Analysis (0)]
55.  Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719-734.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2178]  [Cited by in RCA: 2117]  [Article Influence: 176.4]  [Reference Citation Analysis (41)]
56.  Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25:735-747.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1792]  [Cited by in RCA: 1740]  [Article Influence: 145.0]  [Reference Citation Analysis (18)]
57.  Chen Y, Kim J, Yang S, Wang H, Wu CJ, Sugimoto H, LeBleu VS, Kalluri R. Type I collagen deletion in αSMA(+) myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell. 2021;39:548-565.e6.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 494]  [Cited by in RCA: 481]  [Article Influence: 96.2]  [Reference Citation Analysis (6)]
58.  Hutton C, Heider F, Blanco-Gomez A, Banyard A, Kononov A, Zhang X, Karim S, Paulus-Hock V, Watt D, Steele N, Kemp S, Hogg EKJ, Kelly J, Jackstadt RF, Lopes F, Menotti M, Chisholm L, Lamarca A, Valle J, Sansom OJ, Springer C, Malliri A, Marais R, Pasca di Magliano M, Zelenay S, Morton JP, Jørgensen C. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. Cancer Cell. 2021;39:1227-1244.e20.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 145]  [Cited by in RCA: 281]  [Article Influence: 56.2]  [Reference Citation Analysis (1)]
59.  Cumming J, Maneshi P, Dongre M, Alsaed T, Dehghan-Nayeri MJ, Ling A, Pietras K, Patthey C, Öhlund D. Dissecting FAP+ Cell Diversity in Pancreatic Cancer Uncovers an Interferon-Response Subtype of Cancer-Associated Fibroblasts with Tumor-Restraining Properties. Cancer Res. 2025;85:2388-2411.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 41]  [Cited by in RCA: 38]  [Article Influence: 38.0]  [Reference Citation Analysis (0)]
60.  Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O'Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159:80-93.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1010]  [Cited by in RCA: 963]  [Article Influence: 80.3]  [Reference Citation Analysis (6)]
61.  Hüttner FJ, Klotz R, Giese NA, Kong B, Ahmed A, Merz D, Pöchmann A, Burghaus I, Hackert T, Strobel O, Mihaljevic AL, Michalski CW, Büchler MW, Diener MK. Pancreatic resection with perioperative drug repurposing of propranolol and etodolac - the phase II randomized controlled PROSPER trial. Langenbecks Arch Surg. 2025;410:168.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 11]  [Cited by in RCA: 10]  [Article Influence: 10.0]  [Reference Citation Analysis (0)]
62.  Udumyan R, Montgomery S, Fang F, Almroth H, Valdimarsdottir U, Ekbom A, Smedby KE, Fall K. Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma. Cancer Res. 2017;77:3700-3707.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 60]  [Cited by in RCA: 93]  [Article Influence: 10.3]  [Reference Citation Analysis (0)]
63.  Syeda R, Xu J, Dubin AE, Coste B, Mathur J, Huynh T, Matzen J, Lao J, Tully DC, Engels IH, Petrassi HM, Schumacher AM, Montal M, Bandell M, Patapoutian A. Chemical activation of the mechanotransduction channel Piezo1. Elife. 2015;4:e07369.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 294]  [Cited by in RCA: 596]  [Article Influence: 54.2]  [Reference Citation Analysis (0)]
64.  Bae C, Sachs F, Gottlieb PA. The mechanosensitive ion channel Piezo1 is inhibited by the peptide GsMTx4. Biochemistry. 2011;50:6295-6300.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 427]  [Cited by in RCA: 466]  [Article Influence: 31.1]  [Reference Citation Analysis (3)]
65.  Thien ND, Hai-Nam N, Anh DT, Baecker D. Piezo1 and its inhibitors: Overview and perspectives. Eur J Med Chem. 2024;273:116502.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 59]  [Reference Citation Analysis (0)]
66.  Kinsella JA, Debant M, Parsonage G, Morley LC, Bajarwan M, Revill C, Foster R, Beech DJ. Pharmacology of PIEZO1 channels. Br J Pharmacol. 2024;181:4714-4732.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 14]  [Cited by in RCA: 42]  [Article Influence: 21.0]  [Reference Citation Analysis (0)]
67.  Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO, Pan D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26:1300-1305.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 892]  [Cited by in RCA: 1257]  [Article Influence: 89.8]  [Reference Citation Analysis (1)]
68.  Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M, Kent E, Bown SG, Hasan T, Pogue BW, Pereira SP. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014;110:1698-1704.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 334]  [Cited by in RCA: 314]  [Article Influence: 26.2]  [Reference Citation Analysis (3)]
69.  Yap TA, Kwiatkowski DJ, Dagogo-Jack I, Offin M, Zauderer MG, Kratzke R, Desai J, Body A, Millward M, Tolcher AW, Raghav KPS, Thurston A, Post L, Dorr FA, Tang TT, Li Y, Sharma N, Kindler HL. YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial. Nat Med. 2025;31:4281-4290.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 7]  [Cited by in RCA: 58]  [Article Influence: 58.0]  [Reference Citation Analysis (0)]
70.  Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010;328:1031-1035.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 896]  [Cited by in RCA: 851]  [Article Influence: 53.2]  [Reference Citation Analysis (24)]
71.  Dean A, Gill S, McGregor M, Broadbridge V, Järveläinen HA, Price T. Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study. Lancet Gastroenterol Hepatol. 2022;7:943-951.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 62]  [Cited by in RCA: 65]  [Article Influence: 16.3]  [Reference Citation Analysis (1)]
72.  Kessler L, Hirmas N, Pabst KM, Hamacher R, Ferdinandus J, Schaarschmidt BM, Milosevic A, Nader M, Umutlu L, Uhl W, Reinacher-Schick A, Lugnier C, Witte D, Niedergethmann M, Herrmann K, Fendler WP, Siveke JT. (68)Ga-Labeled Fibroblast Activation Protein Inhibitor ((68)Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the (68)Ga-FAPI PET Observational Trial. J Nucl Med. 2023;64:1910-1917.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 32]  [Reference Citation Analysis (0)]
73.  Li X, Lu N, Sun K, Shi F, Lin L, Chen Y, Wang Y, Wang M, Sun K, Xue X, Xiao W, Su X, Bai X, Liang T. [(18)F]FAPI- 04 PET/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment. Eur J Nucl Med Mol Imaging. 2025;52:3938-3950.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 9]  [Cited by in RCA: 10]  [Article Influence: 10.0]  [Reference Citation Analysis (0)]
74.  Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110:20212-20217.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1768]  [Cited by in RCA: 1755]  [Article Influence: 135.0]  [Reference Citation Analysis (9)]
Footnotes

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Corresponding Author's Membership in Professional Societies: China Association of Acupuncture and Moxibustion, No. M127000218M.

Specialty type: Oncology

Country of origin: China

Peer-review report’s classification

Scientific quality: Grade C, Grade C

Novelty: Grade C

Creativity or innovation: Grade C

Scientific significance: Grade C, Grade C

P-Reviewer: Liu YH, MD, PhD, Professor, China S-Editor: Qu XL L-Editor: A P-Editor: Lei YY

Write to the Help Desk